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Current interest in the MUC1/EMA mucin relates to its role in malignancy, and its potential as a therapeutic target. MUC1/EMA
expression has been observed in the majority of epithelioid mesotheliomas. However, little is known of the characteristics of MUC1/
EMA in mesothelioma. Herein, we studied the cell surface and soluble expression of the MUC1/EMA glycoprotein, and determined
the mRNA and genomic expression profiles in mesothelioma. We found that the anti-MUC1 antibody, E29, was the most
diagnostically useful of seven antibody clones examined with a sensitivity of 84% (16 out of 19 cases) and no false positive results.
MUC1 mRNA expression was significantly higher in mesothelioma samples than in benign mesothelial cells. No amplification of the
MUC1 gene was observed by FISH. Seven of 9 mesothelioma samples expressed MUC1-secreted mRNA isoform in addition to the
archetypal MUC1/transmembrane form. CA15.3 (soluble MUC1) levels were significantly higher in the serum of mesothelioma
patients than in healthy controls but were not significantly different to levels in patients with benign asbestos-related disease. CA15-3
in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma. Thus, as in other cancers,
alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for
mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
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The human MUC1 gene encodes a protein which undergoes
glycosylation and has been variously referred to as epithelial
membrane antigen (EMA), human milk fat globule antigen, breast-
cancer associated DF3 antigen, polymorphic epithelial mucin,
sialomucin, CD227, episialin and CA15-3 (Taylor-Papadimitriou
et al, 2002). The major isoform of the MUC1 gene consists of
a high molecular weight glycosylated extracellular domain, a
variously amplified 20 amino acid repeat sequence (designated the
variable number tandem repeat (VNTR) region), and a hydrophobic
31 amino acid transmembrane domain with a 69 amino acid
cytoplasmic tail (Gendler and Spicer, 1995). This isoform of MUC1,
generally designated simply as MUC1, or MUC1/transmembrane
(MUC1-TM), is expressed on the apical cell surface of the normal
glandular epithelium of many tissues, and also on various
haematopoietic cells. The MUC1 gene products have been intensely
investigated and alterations in expression, splicing patterns, secre-
tion and glycosylation patterns have been observed in many
malignant conditions. These malignancy-associated variations sug-
gest that MUC1 may be an attractive target for anticancer therapies.
Recent studies of MUC1-targeted therapies in lung, prostate and
ovarian malignancies (Loveland et al, 2006; North et al, 2006) show
therapeutic promise. As the majority of epithelioid mesotheliomas
demonstrate strong MUC1/epithelial membrane antigen (EMA)
positivity by immunohistochemistry (Ordonez, 2003) similar anti-
MUC1 therapeutic strategies may have potential in mesothelioma.
Malignant mesothelioma is an aggressive tumour with a median
survival of less than 12 months and limited treatment options
(Robinson et al, 2005).
Although controversial, EMA staining has a role in the diagnosis
of mesothelioma, particularly by effusion cytology distinguishing
malignant mesothelioma cells from benign reactive mesothelial
cells (Wolanski et al, 1998; Whitaker, 2000). The controversy is in
part due to the anti-EMA antibody clone used in studies (Saad
et al, 2005) as a variety of antibodies have been generated against
the various heterogeneous MUC1 protein and glycoprotein
isoforms that have been found in different tissues
and malignant states.
Received 10 October 2007; revised 4 March 2008; accepted 10 March
2008; published online 29 April 2008
*Correspondence: Dr J Creaney, School of Medicine and Pharmacology,
University of Western Australia, 4th Floor, G block, QE2MC, Verdun St,
Nedlands, WA 6009, Australia; E-mail: creaneyj@cyllene.uwa.edu.au
British Journal of Cancer (2008) 98, 1562–1569
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sIn this paper, we have examined various aspects of the MUC1
molecule in malignant mesothelioma effusion and tissue samples
to investigate its potential diagnostic role, mRNA expression,
splice variants, and used fluorescence in situ hybridisation (FISH)
to detect gene amplification. In addition, we have examined levels
of CA15-3 (a secreted form of MUC1) in serum and effusion
supernatant. These studies aim to provide a baseline analysis of
mesothelioma-associated MUC1 isoforms, and also to determine
which mesothelioma-specific features of MUC1 may be of potential
diagnostic and therapeutic relevance in this disease.
MATERIALS AND METHODS
Patients, samples and controls
Serum, pleural effusion and surgically-excised tumour tissue
samples were collected from patients following written informed
consent. All biospecimens were provided by the Australian
Mesothelioma Tissue Bank, a member of the ABN-oncology
group, which is supported by the National Health and Medical
Research Council, Australia. This study was approved by the
human research ethics committees of Sir Charles Gairdner and
Hollywood Hospitals, Perth, Western Australia. The final diagnosis
in all patients was confirmed by pathologists experienced in the
diagnosis of mesothelioma and included clinical follow-up of all
cases until death or to last citation in the Public Hospital database
system (iSoft Clinical Manager) to confirm that the clinical pattern
matched the diagnosis. Mesotheliomas were classified as epithelial,
sarcomatoid, mixed or, in cases where diagnosis was made on the
basis of immunocytology and there was no histological follow-up,
as unspecified.
Normal mesothelial cells were recovered from pericardial fluid
obtained from patients undergoing intrathoracic surgery as
described previously (Holloway et al, 2006). Serum samples were
collected from healthy volunteers, and from patients with the
asbestos-related lung disease, asbestosis, and the asbestos-related
pleural disease, pleural plaques. Pleural effusion samples were
collected from patients with effusions caused by nonmesothelioma
malignancy. Effusions were classified as benign (i.e., nonmalig-
nant) on the basis of cytological and immunohistochemical
features, and further classified as exudates or transudates on the
basis of Light’s criteria (Light et al, 1972). Effusions were classified
as being associated with an infection if micro-organisms were
detected in the fluid. Patient characteristics are listed in Table 1.
Immunohistochemistry
A tissue microarray was constructed by the Western Australian
Research Tissue Network (Perth, Western Australia) from archival
paraffin blocks. The tissue microarray contained effusion cell
pellets from 20 cases of malignant mesothelioma and 16 cases of
benign-reactive pleural effusions. Immunohistochemistry was
performed using standard techniques. Briefly, sections were
deparaffinised with xylene and rehydrated in a graded series of
ethanol. Antigen-retrieval was performed for 10min at high
temperature in citrate buffer. Sections were incubated with anti-
EMA clones for 60min and washed in PBS. Immunodetection
was performed using Envisionþ Dual link detection system
(Dako, Glostrup, Denmark). For negative controls, the primary
antibody was omitted. Antibodies were purchased from various
suppliers (Table 2). Some of these antibodies had been previously
characterised by workshops organised by the International Society
of Oncodevelopmental Biology and Medicine (ISOBM) in terms of
the epitope recognised within the VNTR and whether that
recognition was dependent upon the glycosylation status of the
epitope. These antibodies were assigned to various classes or
clusters by the ISOBM workshops based upon their staining profile
on normal breast tissue samples (summarised in Table 2)
(Cao et al, 1998; Hanisch, 1998).
Staining was assessed by three observers independently (JC, AS
and GS). A positive result was defined as the presence of
membranous staining on tumour cells. Staining intensity was
graded semi-quantitatively as negative, equivocal (þ/ ), weak
(1þ), moderate (2þ) or strong (3þ). Moderate and strong
positivity was only assigned where the majority of cells showed
positive staining. Sensitivity was calculated as the total number of
moderately and strongly stained mesothelioma samples divided by
the total number of mesothelioma samples. Specificity was
calculated as the number of negative benign control samples
divided by the total number of benign control samples. False
positive rate was calculated as the number of moderately and
strongly stained benign samples divided by the total number of
benign samples.
Quantitative PCR
RNA was extracted using Rneasy kits (Qiagen, Clifton Hill,
Victoria, Australia), following the manufacturer’s protocol. cDNA
was generated in a standard reverse transcriptase reaction using
oligo dT to prime Superscript II (Invitrogen, Mt Waverly,
Victoria, Australia). Quantitative PCR was performed with specific
primer sets (MUC1 forward 50-AGACGTCAGCGTGAGTGATG-30;
reverse 50-GACAGCCAAGGCAATGAGAT-30) (Ohuchida et al,
2006) on the iCycler iQ Real Time Detection System (BioRad,
Gladesville, New South Wales, Australia) using the QuantiTech
SYBR Green PCR Kit (Qiagen). The primers correspond to
nucleotides 4757–5017 of the human polymorphic epithelial
mucin gene (GeneBank Accession number M61170) and amplify
the MUC1-TM product. The relative expression of MUC1-TM was
calculated using the standard delta Ct formula as follows:
x ¼ 2DCt; whereDCtðMUCI-TMÞ CtðGAPDHÞ
Fish
4mm sections from the tissue microarray were deparaffinised,
dehydrated, microwave treated in citrate buffer (pH 6.0)
for 10min, digested in pepsin solution (4mgml
 1 in 0.01N HCl)
Table 1 Patient characteristics
Condition
Number
of cases
Age
(Mean±s.d.)
Histology or
tumour type
Mesothelioma 60 71.2±11.7 29 epithelial
16 unspecified
Nine mixed
Six sarcomatoid
Benign effusions 39 73±13.7 23 exudate
Seven
exudate–infection
Nine transudate
Controls
Normal mesothelial cells 7 64.5±10
Healthy volunteers 24 48.7±12.8
Asbestosis patients 11 67.2±11.4
Asbestosis patients
with pleural plaques
21 70.2±12.7
Other maligancies 26 67.2±12.7 19 lung cancer
Three lymphoma
Four other
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citrate (pH 7.0) at room temperature for 5min. Dual-probe
hybridisation was performed using three SpectrumGreen-labeled
BAC clones which encompass the MUC1 gene at 1q22, plus a
SpectrumOrange-labeled chromosome 1 centromeric probe (Vysis,
Downers Grove, IL, USA) as a control. Seventeen mesothelioma
samples were available for FISH analysis.
Conventional PCR
Conventional PCR was performed with specific primer sets
designed for different splice forms as described by (Obermair
et al, 2002) and using Taq DNA polymerase (Qiagen). The primer
pair Muc1-F (GCACTCACCATAGCACG) and Muc1-R (GGCCA-
GAGTCAATTGTAC) distinguish between MUC1-TM and a
secreted MUC1 isoform, containing the VNTR but lacking the
transmembrane domain and cytoplasmic tail, MUC1/secreted
(SEC). PCR products were separated by electrophoresis on 3.5%
agarose gel and visualised under UV light with ethidium bromide.
Measurement of CA15-3
CA15-3 levels were determined using the IMMULITE 2000 BR-MA
(CA15-3) assay (Diagnostic Products Corporation, Los Angeles,
CA, USA) according to the manufacturer’s instructions. The assay
is a sandwich ELISA utilising the monoclonal antibodies 115D8
and DF3. A value above 53kUl
 1 was considered to be outside the
normal range of healthy persons. All assays were performed on
coded samples by technical staff unaware of the patient’s
diagnosis.
Statistics
To test for statistically significant differences biomarkers were
transformed to the logarithmic scale on which normal theory
statistical estimates (mean, s.d.) and tests (t-tests) were applied.
RESULTS
EMA staining by Immunohistochemistry
The pattern of staining for all antibodies examined was similar,
with accentuated staining detectable on the cell membrane
(Figure 1). The sensitivity of the different antibody clones for
mesothelioma effusion samples ranged from 25% for the VU2G7
and VU4H5 clones to 100% for the Mc5 clone. The E29 clone
reacted with 16 (of 19) specimens (Table 3). Most of the antibodies
studied were highly specific for malignant cells with no moderate
or strongly stained cells being observed in up to 16 specimens of
benign reactive effusion studied (Table 3). However the Mc5 clone
reacted strongly with over half of the nonmalignant samples (57%
false-positive rate). The MA695 clone had weak or equivocal
staining on two thirds of these control samples (Table 3). The
pattern of reactivity of the Mc5 clone was membrane accentuated
in both the malignant and benign specimens.
MUC1 mRNA is overexpressed in mesothelioma cells
The relative expression of the archetypal, full-length, transmem-
brane MUC1 isoform, MUC1-TM, normalised to GAPDH, was
significantly greater in the cells from pleural effusion (Po0.0001)
and surgically-excised tumour (P¼0.001) mesothelioma samples
than that in normal mesothelial cells (Figure 2). Median expression
levels were two to threefold greater in malignant mesothelioma
samples than in normal mesothelial cells. Expression of MUC1-TM
in cells from mesothelioma effusions were significantly greater
(Po0.005) than in effusions with benign reactive mesothelial cells.
This overexpression was not due to gene amplification as there was
no amplification of MUC1 by FISH (data not shown). There was no
significant difference in relative levels of MUC1-TM between
normal mesothelial cells and from cells obtained from patients
with effusions of nonmalignant origin (Figure 2).
Alternative splice forms of MUC1
Conventional PCR using primers distinguishing MUC1-TM from a
secreted isoform of MUC1 which lacks the transmembrane region,
MUC1-SEC, demonstrated that approximately half of the samples
from malignant mesothelioma cells either from solid tumour or
from effusions expressed MUC1-SEC in addition to the transmem-
brane form (Figure 3). Normal mesothelial cells, either from
pericardial fluid or from benign reactive effusions predominately
expressed the full length MUC1-TM isoform.
Serum CA15-3 level
The median concentration of CA15-3 in the serum of patients
with malignant mesothelioma was 57.4±2.5kUl
 1 (range,
13–1321kUl
 1); 35% (17 out of 49) of mesothelioma patients
had serum CA15-3 above the upper limit of normal (53kUl
 1)
(Figure 4A). Though patient numbers were limited, mesothelioma
Table 2 Anti-EMA antibodies used in this study
Clone Source Antigen Epitope
Group/Class Staining on
T-47D breast cancer cells
a Cluster
a Ref
E29 Dako, Glostrup, Denmark Delipidated HMFG
b APDTRP Group A–PAN
c
Membrane & golgi
2 (Cordell et al, 1985)
Mc5 Neomarkers Fremont, CA, USA Delipidated HMFG DTRPAP Group A–PAN
Membrane & trans-golgi
2 (Peterson et al, 1995)
VU2G7 Chemicon Europe 3 VNTR-galNAc PDTR NA NA (Ryuko et al, 2000)
VU4H5 Santa Cruz, CA, USA 3 VNTR (nonglycosylated) PDTR Group B3–Differentiation dependent
d
Cytoskeletal-like
2 (Ryuko et al, 2000)
CBL263
(VU3C6)
Chemicon Europe Breast Ca cell line ZR75.1 PDTRPAP Group B2–Differentiation dependent
Golgi 4membrane
7A
MA552 NovaCastra Newcastle upon Tyne Breast Ca cell line ZR75.1 TRPAPG Group B1–Differentiation dependent
Golgi 4membrane
7A (Baeckstrom et al, 1993)
MA695 NovaCastra Breast Ca cell line ZR75.1 CHO epitope Group A–PAN
Membrane & golgi
7B&C
aData modified from workshop reports of the International Society for Oncodevelopmental Biology and Medicine (ISOBM) (Cao et al, 1998; Hanisch, 1998).
bHMFG–human
milk fat globulin.
cPAN–staining occurred in normal breast, intestine and colon.
dDifferentiation-dependent staining in benign breast, intestine and/or colon occurred following
periodate treatment. Cluster 2–reacts with synthetic peptide; the binding is affected by in vitro glycosylation; Cluster 7–reacts with carbohydrate or conformational epitope.
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spatients with a sarcomatoid or mixed histology had lower serum
concentrations of CA15-3 than mesothelioma patients with a
predominately epitheliod histology (Figure 4B).
Median CA15-3 concentration in patients with benign asbestos-
related disease (either asbestosis and/or pleural plaques) was
38±6kUl
 1 (range, 14–155kUl
 1); 28% (9 out of 32) of patients
with asbestos-related benign disease had CA15-3 levels above the
upper limit of normal. There was no significant difference in
serum CA15-3 between patients with mesothelioma and patients
with benign asbestos-related lung and pleural disease. One of 10
patients with non-malignant pleural effusions examined had
elevated serum CA15-3. Median CA15-3 concentration in the
serum of healthy controls was 22±2kUl
 1 (range, 9–43kUl
 1).
Median concentrations of CA15-3 were significantly higher in the
serum of mesothelioma patients compared to patients with benign
effusions (P¼0.016) and normal controls (Po0.0001) (Figure 4A).
Effusion CA15-3 level
Levels of CA15-3 in pleural effusions of patients with malignant
mesothelioma ranged from undetectable to 2614kUl
 1, with a
median of 36.9±3.9kUl
 1. Approximately 38% (20 out of 52) of
mesothelioma patients had CA15-3 levels above the upper limit of
normal (53kUl
 1) (Figure 4C). Mesothelioma patients with
sarcomatoid histology had lower levels of CA15-3 in their effusion
than mesothelioma patients with predominately epitheliod
Figure 1 Immunohistochemical staining for MUC1/EMA on sections of formalin-fixed paraffin-embedded cell pellets from pleural fluid specimens. (A, C
and E) are cells from a patient with mesothelioma. (B, D and F) are benign reactive mesothelial cells from a patient with a nonmalignant effusion. (A and B)
were stained with the anti-EMA clone E29; (C and D) with the VU2G7 clone and (E and F) with the Mc5 clone.
Table 3 Sensitivity, specificity and false-positive rate of anti-EMA
antibodies assessed by immunocytology on confirmed mesothelioma
effusions and cases of benign reactive effusions
Anti-EMA clone Sensitivity Specificity False positives
VU2G7 5/20 (25%) 16/16 (100%) 0%
VU4H5 5/20 (25%) 16/16 (100%) 0%
CBL263 (VU3C6) 6/19 (32%) 15/15 (100%) 0%
MA552 9/18 (50%) 12/13 (92%) 0%
MA695 14/20 (70%) 5/15 (33%) 0%
E29 16/19 (84%) 14/15 (93%) 0%
Mc5 20/20 (100%) 0/14 (0%) 8/14 (57%)
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groups (Figure 4D).
The median CA15-3 concentration in the effusions of patients
with nonmesothelioma malignancies was 24±6kUl
 1 (range,
13–191kUl
 1); CA15-3 was elevated in 24% (6 out of 25) of
effusions from these patients. There was no significant difference
in the effusion CA15-3 levels between the groups of patients with
mesothelioma or other malignancy. Median CA15-3 in effusions of
nonmalignant origin was 8.5±2.9kUl
 1 (range from undetectable
to 42kUl
 1). CA15-3 levels were statistically significantly higher in
the effusions of patients with mesothelioma than those with benign
effusions (P¼0.004) (Figure 4C).
DISCUSSION
Normal/reactive nonmalignant mesothelial cells express predomi-
nantly the full-length tandem-repeat containing MUC1-TM, which
can be detected on the cell membrane by the Mc5 antibody. In
cases of malignant mesothelioma there is an increase in the total
quantity of MUC1-TM mRNA expressed, a change in the type of
MUC1 isoform produced, an alteration in the epitopes of MUC1
expressed on cell surface and an increase in MUC1 gene product
detectable in the circulation.
The Mc5 antibody was generated against delipidated human
milk fat globule and recognises the DTRPAP epitope in the VNTR
of the MUC1-TM protein (Peterson et al, 1995). In the current
study the Mc5 antibody recognised membrane associated antigen
on mesothelial cells in over half of the effusion samples of
nonmalignant origin examined and mesothelioma cells in all of the
effusions associated with malignant mesothelioma. Saad et al
(2005) demonstrated that the choice of antibody clone could
greatly influence the accuracy of the use of anti-MUC1/EMA
antibodies in distinguishing benign from malignant mesothelial
cells in a diagnostic setting . This may be one factor in the debate
regarding the role of EMA immunohistochemistry in mesothelio-
ma diagnosis. The E29 clone and four of the other clones examined
did not recognise MUC1 expressed on benign mesothelial cells.
The E29 clone was also generated against delipidated human milk
fat globule and recognises an overlapping epitope (the APDTRP
epitope) to that recognised by Mc5. It is noteworthy that the E29
clone stains normal breast, intestine and colon. Alteration in
MUC1 glycosylation has been reported in many malignancies
(Baldus et al, 2004). The current antibody studies suggest that
glycosylation of MUC1-TM is altered in malignant mesothelioma
cells. However, the actual nature of the alteration is unclear at
present. The finding of different staining profiles with the two
antibodies, Mc5 and E29, which belong to the same group,
recognise the same epitope and are both affected by in vitro
glycosylation needs to be further investigated.
Levels of MUC1 gene product in serum and effusions can be
determined by several tests, the most common being the CA15-3,
mucin-like associated antigen, CA27.29 and CA549 assays.
Differences between these tests derived from the monoclonal
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Figure 2 Relative expression of full length, transmembrane MUC1-TM
normalised to GAPDH determined by quantitative PCR. Mean results for
individual samples are indicated by diamonds, open diamonds are
nonmalignant samples and closed diamonds are malignant samples. Mean
levels for each group are indicated by the horizontal bar. Expression was
determined in normal mesothelial cells derived from pericardial cells; cells
from benign reactive pleural effusions (PE-BRM); mesothelioma samples
from pleural effusions (PE-MM); and 10 mesothelioma tumour samples
(Tumour-MM). ***Po0.0001; **Po0.005.
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Figure 4 CA15-3 in mesothelioma patients and controls (A) Serum CA15-3 levels were determined in duplicate and individual patient values are plotted
on the graph. Serum CA15-3 were plotted for malignant mesothelioma (MM) patients, individuals who had asbestosis and who had asbestosis and pleural
plaques (asb. and plaques), patients with effusions containing benign reactive mesothelial cells (PE-BRM) and for control, healthy individuals with no
documented asbestos exposure. (B) CA15-3 levels in mesothelioma patients segregated by tumour histology. Mesothelioma patients were characterised by
the histology of the tumour (sarcomatoid, mixed histology or epithelial), or in those cases where diagnosis was made without histology being reported
(unspecified). (C) CA15-3 levels were determined in effusions from mesothelioma patients (closed diamonds), from individuals with malignant effusions not
due to mesothelioma (closed triangles), and from nonmalignant effusions of an exudative, or transudate nature or relating to an infection (open diamonds).
(D) Pleural effusion CA15-3 of patients with malignant mesothelioma further characterised by the histology of the tumour (sarcomatoid, biphasic, epithelial
or unspecified). The manufacturer defined upper limit of normal concentration (53kUl
 1) is depicted by the hashed horizontal line.
Table 4 CA15.3 in serum and pleural effusions
Sample population n Mean Median Positive (%) (453Uml
 1) Significance level
a
Serum
Mesothelioma 49 100±189 47 17 (35%)
Normal 24 21.5±9.7 21 0 Po0.0001
Asbestos-exposed benign disease 32 52±34 38 9 (28%) ns
Benign effusions 11 34±26 32.6 1 (9%) P¼0.016
Effusion
PE mesothelioma 51 69±107 24 17 (33%)
PE benign 30 10±10 8.5 0 ns
PE malignancy 25 66±112 24 7 (28%) P¼0.004
aLevel of significance relative to samples from patients with mesothelioma.
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antibodies to the level of glycosylation of the protein (Klee and
Schreiber, 2004). In the current study, the CA15-3 assay was used.
The major clinical role of CA15-3 biomarker is in monitoring
breast carcinoma metastases and the evaluation of response to
treatment. CA15-3 has previously been found in several small scale
studies to be elevated in the serum (Alatas et al, 2001) and in
effusions of patients with mesothelioma (Miedouge et al, 1999;
Alatas et al, 2001) (Villena et al, 2003). In the current study,
CA15-3 levels were significantly higher in the serum of meso-
thelioma patients than healthy controls; however, the finding that
levels were elevated in patients with benign lung and pleural
disease suggests that serum CA15-3 will not be useful as a
diagnostic aid for mesothelioma. Elevated levels of CA15-3 in
effusions may be a strong indicator of malignancy in general as
previously suggested (Shitrit et al, 2005).
The MUC1 gene product detected in the circulation by the
CA15-3 assay contains the VNTR region, therefore the protein may
be the archetypal MUC1-TM protein that has been released or
cleaved from the cell surface, or may be one of the secreted
isoforms. There is some evidence to suggest the latter as the
MUC1-SEC was detected by PCR in some of the samples derived
from mesothelioma patients, but not from normal mesothelial
samples or from cells in the nonmalignant pleural effusions
examined. Interestingly, the lack of MUC-SEC expression has been
associated with ovarian cancer (Obermair et al, 2002). Our study
used both clinical samples and, in an attempt to limit the influence
of nonmesothelial cellular infiltrates, also in vitro cultured
homogeneous pericardial cells. It was encouraging to find
generally a good correlation between the two sample types, as
one concern was that alternative splicing of MUC1 might reflect
changes induced by culture.
While the secreted splice form was detected in malignant
mesothelial cells, it is of particular note that the expression of the
full length, VNTR containing MUC1 gene product was 32-fold
higher in mesothelioma than in normal cell preparations. Evidence
suggests that this overexpression was not due to a gene
amplification event, but to an as yet unknown mechanism.
MUC1 overexpression is associated with poor prognosis in breast
(Rakha et al, 2005) and lung adenocarcinoma (Tsutsumida et al,
2004); however, its influence in the prognosis of mesothelioma has
not been reported.
Various forms of MUC1 are expressed in mesothelioma. We
suggest that the specific hypoglycosylated form of the full length
tandem repeat containing MUC1 protein product is a useful target
for mesothelioma diagnosis, but possibly the expression of novel
MUC1 epitopes may represent a potential therapeutic target.
Currently there are promising MUC1 directed therapies being
investigated in breast, ovarian and non small cell lung cancer.
These include therapies targeting MUC1-associated carbohydrates
such as sialyl-Tn (STn, Theratope), MUC1-pulsed dendritic cell
vaccines and also the MUC1 peptide-based vaccine BLP-25
(Brossart et al, 2000; Morse, 2001; Miles and Papazisis, 2003;
Wierecky et al, 2006a,b). Our findings suggest that the role of
MUC1-directed therapy in mesothelioma should be investigated.
ACKNOWLEDGEMENTS
We would like to acknowledge the expert technical assistance of
Ms Deborah Yeoman and Mr Steve Fletcher. This work was
supported in part by the Insurance Commission of Western
Australia, and by PathWest Laboratory Medicine.
REFERENCES
Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S (2001)
Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA
assay in pleural effusions. Lung Cancer 31: 9–16
Baldus SE, Engelmann K, Hanisch FG (2004) MUC1 and the MUCs: a family
of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41:
189–231
Baeckstrom D, Nilsson O, Price MR, Lindholm L, Hansson GC (1993)
Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glyco-
proteins produced by colon carcinoma cells using a novel monoclonal
antibody. Cancer Res 53(4): 755–761
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000)
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations
with peptide-pulsed dendritic cells. Blood 96: 3102–3108
Cao Y, Cao Y, Karsten U, Hilgers J (1998) Immunohistochemical
characterization of a panel of 56 antibodies with normal human
small intestine, colon, and breast tissues. Tumour Biol 19(Suppl 1):
88–99
Cordell J, Richardson TC, Pulford KA, Ghosh AK, Gatter KC, Heyderman E,
Mason DY (1985) Production of monoclonal antibodies against human
epithelial membrane antigen for use in diagnostic immunocyto-
chemistry. Br J Cancer 52(3): 347–354
Hanisch FG (1998) Specificity clusters of MUC1-reactive mouse mono-
clonal antibodies. Tumour Biol 19(Suppl 1): 111–117
Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW,
Lake RA, Bowtell DD (2006) A molecular diagnostic test for
distinguishing lung adenocarcinoma from malignant mesothelioma
using cells collected from pleural effusions. Clin Cancer Res 12:
5129–5135
Klee GG, Schreiber WE (2004) MUC1 gene-derived glycoprotein assays for
monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring
the same antigen? Arch Pathol Lab Med 128: 1131–1135
Light RW, Macgregor MI, Luchsinger PC, Ball Jr WC (1972) Pleural
effusions: the diagnostic separation of transudates and exudates. Ann
Intern Med 77: 507–513
Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA,
Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF,
Mitchell PL (2006) Mannan-MUC1-pulsed dendritic cell immunotherapy: a
phase I trial in patients with adenocarcinoma. Clin Cancer Res 12: 869–877
Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA,
Reyre J, Carles P, Serre G (1999) Evaluation of seven tumour markers in
pleural fluid for the diagnosis of malignant effusions. Br J Cancer 81:
1059–1065
Miles D, Papazisis K (2003) Rationale for the clinical development of STn-
KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast
Cancer 3(Suppl 4): S134–S138
Morse MA (2001) Technology evaluation: BLP-25, Biomira Inc.. Curr Opin
Mol Ther 3: 102–105
North SA, Graham K, Bodnar D, Venner P (2006) A pilot study of the
liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after
radical prostatectomy. J Urol 176: 91–95
Obermair A, Schmid BC, Packer LM, Leodolter S, Birner P, Ward BG,
Crandon AJ, McGuckin MA, Zeillinger R (2002) Expression of MUC1
splice variants in benign and malignant ovarian tumours. Int J Cancer
100: 166–171
Ohuchida K, Mizumoto K, Yamada D, Fujii K, Ishikawa N, Konomi H,
Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M (2006) Quantitative
analysis of MUC1 and MUC5AC mRNA in pancreatic juice for
preoperative diagnosis of pancreatic cancer. Int J Cancer 118: 405–411
Ordonez NG (2003) The immunohistochemical diagnosis of mesothelioma:
a comparative study of epithelioid mesothelioma and lung adenocarci-
noma. Am J Surg Pathol 27: 1031–1051
Peterson JA, Couto JR, Taylor MR, Ceriani RL (1995) Selection of tumor-
specific epitopes on target antigens for radioimmunotherapy of breast
cancer. Cancer Res 55: 5847s–5851s
Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC,
Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2,
MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in
human breast cancer. Mod Pathol 18: 1295–1304
MUC1/EMA in malignant mesothelioma
J Creaney et al
1568
British Journal of Cancer (2008) 98(9), 1562–1569 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sRobinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet
366: 397–408
Ryuko K, Schol DJ, Snijdewint FG, von Mensdorff-Pouilly S,
Poort-Keesom RJ, Karuntu-Wanamarta YA, Verstraeten RA,
Miyazaki K, Kenemans P, Hilgers J (2000) Characterization of a new
MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated
PDTR sequence of MUC1. Tumour Biol 21(4): 197–210
Saad RS, Cho P, Liu YL, Silverman JF (2005) The value of epithelial
membrane antigen expression in separating benign mesothelial prolife-
ration from malignant mesothelioma: a comparative study. Diagn
Cytopathol 32: 156–159
Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR (2005) Diagnostic
value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in
pleural effusions: analysis of 116 cases and review of the literature.
Oncologist 10: 501–507
Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I,
Miles D, Smith M (2002) MUC1 and the immunobiology of cancer.
J Mammary Gland Biol Neoplasia 7: 209–221
Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Yonezawa S (2004)
Combined status of MUC1 mucin and surfactant apoprotein A
expression can predict the outcome of patients with small-size lung
adenocarcinoma. Histopathology 44: 147–155
Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P,
Ortuno-de-Solo B, Estenoz-Alfaro J (2003) Diagnostic value of CA 549 in
pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer
40: 289–294
Whitaker D (2000) The cytology of malignant mesothelioma. Cytopathology
11: 139–151
Wierecky J, Mueller M, Brossart P (2006a) Dendritic cell-based
cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother
55: 63–67
Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM,
Hantschel M, Brugger W, Schroder S, Horger MS, Kanz L, Brossart P
(2006b) Immunologic and clinical responses after vaccinations with
peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer
Res 66: 5910–5918
Wolanski KD, Whitaker D, Shilkin KB, Henderson DW (1998) The use of
epithelial membrane antigen and silver-stained nucleolar organizer
regions testing in the differential diagnosis of mesothelioma from benign
reactive mesothelioses. Cancer 82: 583–590
MUC1/EMA in malignant mesothelioma
J Creaney et al
1569
British Journal of Cancer (2008) 98(9), 1562–1569 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s